Kolexia
Perol Maurice Pneumologie
Perol Maurice
Pneumologie
Centre Léon-Bérard
Lyon, France
472 Activités
1.4 K Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Carcinome pulmonaire non à petites cellules Tumeurs du poumon Carcinome pulmonaire à petites cellules Métastase tumorale Adénocarcinome Carcinomes Tumeurs du cerveau Carcinome épidermoïde Récidive tumorale locale

Collaborateurs

Voir plus
Moro-Sibilot Denis
Moro-Sibilot Denis
Hôpital Nord Grenoble, La Tronche, France
Chouaid Christos
Chouaid Christos
Centre Hospitalier Intercommunal Créteil, Créteil, France
Girard Nicolas
Girard Nicolas
Clcc Institut Curie, Paris, France
Audigier-Valette Clarisse
Audigier-Valette Clarisse
Centre Hospitalier Toulon, Toulon, France

Industries

Voir plus
AstraZeneca
77 collaboration(s)
Dernière en 2023
MSD
61 collaboration(s)
Dernière en 2023
Takeda Pharmaceutical
33 collaboration(s)
Dernière en 2023
Sanofi
26 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
RAISE: A Single-arm Phase II Trial of the Addition of Niraparib to Anti-PD-L1 Antibody Maintenance in Patients With SLFN11-positive, Extensive-disease Small Cell Lung Cancer.
Essai Clinique (GSK)   21 mars 2024
LIBRETTO-431: A Multicenter, Randomized, Open-Label, Phase 3 Trial Comparing Selpercatinib to Platinum-Based and Pemetrexed Therapy With or Without Pembrolizumab as Initial Treatment of Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer
Essai Clinique (Loxo Oncology, Inc.)   15 mars 2024
IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE): Official Title: A Phase II Multicenter, Open Label, Non-randomized Study of Neoadjuvant and Adjuvant Treatment With IPH5201 and Durvalumab in Patients With Resectable, Early-stage (II to IIIA) Non-Small Cell Lung Cancer (MATISSE)
Essai Clinique (Innate Pharma)   13 mars 2024
AMAZE-lung: A Multicentre Single-arm Phase II Trial of Amivantamab, Lazertinib Plus Bevacizumab in Patients With EGFR-mutant Advanced NSCLC With Progression on Previous Third-generation EGFR-TKI
Essai Clinique (Janssen)   08 mars 2024
PROFILER: Program to Establish the Genetic and Immunologic Profile of Patient's Tumor for All Types of Advanced Cancer
Essai Clinique (Centre Léon-Bérard)   01 mars 2024
SUNRAY-01, A Global Pivotal Study in Participants With KRAS G12C-Mutant, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing First-Line Treatment of LY3537982 and Pembrolizumab vs Placebo and Pembrolizumab in Those With PD-L1 Expression ≥50% or LY3537982 and Pembrolizumab, Pemetrexed, Platinum vs Placebo and Pembrolizumab, Pemetrexed, Platinum Regardless of PD-L1 Expression
Essai Clinique (Lilly)   27 février 2024
LIBRETTO-432: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib Following Definitive Locoregional Treatment in Participants With Stage IB-IIIA RET Fusion-Positive NSCLC
Essai Clinique (Loxo Oncology, Inc.)   27 février 2024
AcSé CRIZOTINIB : Secured Access to Crizotinib for Patients With Tumors Harboring a Genomic Alteration on One of the Biological Targets of the Drug.
Essai Clinique (Unicancer)   26 février 2024
ERICA: Feasibility of an Acute Physical Exercise Before Immunotherapy and Chemotherapy Infusion for Metastatic Non-small-cell Lung Cancer Patients: Protocol ERICA Study
Essai Clinique (Centre Léon-Bérard)   20 février 2024
Met Non Small Cell Cancer Registry (MOMENT): Disease Registry on Patients With Advanced NSCLC Harboring METex14 Skipping Alterations (MOMENT)
Essai Clinique (Emd Serono)   19 février 2024